Clinical Study of 18F-FAPI-RGD in Breast Tumors

Status Recruiting

Clinical Trial Summary

The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Breast Tumors. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

Clinical Trial Description

Breast cancer is the most common malignant disease in women worldwide.Early detection, accurate diagnosis and staging are the keys to effective treatment for breast cancer patients.18F-FDG PET/CT has become an important imaging method for the diagnosis and staging of breast cancer.However,FDG PET has certain limitations, including false-positive uptake for acute and chronic infections and false-negative uptake for less aggressive histological subtypes of breast cancer.In a number of studies, 68Ga-FAPI PET was positively correlated with the pathological grade and end-stage of primary breast cancer lesions, and SUVmax could predict tumor grade, final stage and lymph node metastasis. Compared with 18F-FDG,68Ga-FAPI PET/CT had higher specificity and accuracy in judging lymph node metastasis.Integrin αvβ3 is highly expressed in neovascular endothelial cells and tumor cells including breast cancer, and plays an important role in regulating tumor growth, angiogenesis, local invasion and metastasis potential.The use of integrin αvβ3 specific imaging probes derived from RGD peptides in breast cancer patients has also been reported. Several studies have confirmed that the heterodimer is superior to the corresponding monomer due to the polyvalent effect, thus improving the binding affinity and increasing the number of effective receptors.In order to simultaneously target FAP and integrin αvβ3, we synthesized the heterodimeric peptide FAPI-RGD from FAPI and RGD.FAPI-RGD is a heterodimeric peptide that targets FAP and αvβ3-integrin receptors. 68Ga-FAPI-RGDPET/CT imaging has been used in clinical imaging studies in patients with a variety of tumors.Therefore, we plan to use 18F-FAPI-RGD PET/CT imaging for the diagnosis and treatment of breast cancer, and preliminary experiments have confirmed that this examination has a good imaging effect. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05976620
Study type	Observational [Patient Registry]
Source	Sichuan Provincial People's Hospital
Contact
Status	Recruiting
Phase
Start date	June 20, 2023
Completion date	February 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02225470` - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Phase 3
Completed	`NCT01271738` - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer	N/A
Active, not recruiting	`NCT04132960` - Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis	Phase 2
Completed	`NCT01980823` - Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	Early Phase 1
Completed	`NCT01218529` - Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors	Phase 2
Completed	`NCT02891681` - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment	N/A
Terminated	`NCT01498588` - Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer	Phase 2
Completed	`NCT00639171` - Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant
Recruiting	`NCT05582499` - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	Phase 1/Phase 2
Completed	`NCT05584644` - A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Completed	`NCT00243698` - A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions	N/A
Completed	`NCT00807859` - Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer	Phase 1
Completed	`NCT01118624` - Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer	Phase 2
Recruiting	`NCT00941408` - Biomarker Study of Breast Tumors	N/A
Completed	`NCT00626106` - QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer	Phase 2
Recruiting	`NCT01042379` - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Phase 2
Terminated	`NCT02472353` - Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer	Phase 2
Terminated	`NCT01194908` - Re-expression of ER in Triple Negative Breast Cancers	Phase 1/Phase 2
Completed	`NCT02296801` - A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer	Phase 2
Active, not recruiting	`NCT02187991` - Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer	Phase 2